Melan 10mg Tablet contains Methoxsalen 10mg, a psoralen derivative used primarily in the treatment of vitiligo and psoriasis. Methoxsalen acts by intercalating into DNA and, upon exposure to ultraviolet A (UVA) light, forms cross-links that inhibit DNA synthesis and cell proliferation. This photochemotherapy approach, known as PUVA therapy, helps to restore pigmentation in depigmented skin patches and reduce psoriatic lesions. Melan 10mg is indicated for patients requiring controlled photochemotherapy to manage these dermatological conditions. The tablet should be administered orally, typically 1 to 2 hours before UVA exposure, to ensure optimal drug absorption and efficacy. Dosage and treatment duration must be individualized based on patient response and tolerance, with careful monitoring for potential adverse effects such as nausea, headache, and photosensitivity reactions. Caution is advised in patients with hepatic impairment, a history of skin cancer, or those taking other photosensitizing agents. Regular follow-up is essential to assess therapeutic outcomes and minimize risks. Melan 10mg Tablet should be used under strict medical supervision, adhering to recommended guidelines to maximize benefits while reducing the likelihood of phototoxicity and long-term complications.